Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 51, Issue 8, Pages 1911-1920
Publisher
Wiley
Online
2021-06-09
DOI
10.1002/eji.202048994
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
- (2021) D.J. McGrail et al. ANNALS OF ONCOLOGY
- Peripheral T cell expansion predicts tumour infiltration and clinical response
- (2020) Thomas D. Wu et al. NATURE
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy
- (2020) Laura A. Vitale et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
- (2020) Jean-Christophe Beltra et al. IMMUNITY
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- cDC1 dysregulation in cancer: An opportunity for intervention
- (2020) Thomas F. Gajewski et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance
- (2020) Catherine L. Tan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
- (2020) Shogo Kumagai et al. NATURE IMMUNOLOGY
- PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
- (2020) Qi Peng et al. Nature Communications
- Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion
- (2020) Julia Busselaar et al. Frontiers in Immunology
- Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells
- (2019) Sema Kurtulus et al. IMMUNITY
- Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy
- (2019) Imran Siddiqui et al. IMMUNITY
- Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
- (2019) Brian C. Miller et al. NATURE IMMUNOLOGY
- Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
- (2019) Melvyn T. Chow et al. IMMUNITY
- Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
- (2019) Daisuke Sugiura et al. SCIENCE
- STING pathway agonism as a cancer therapeutic
- (2019) Blake A. Flood et al. IMMUNOLOGICAL REVIEWS
- Clonal replacement of tumor-specific T cells following PD-1 blockade
- (2019) Kathryn E. Yost et al. NATURE MEDICINE
- Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
- (2019) Javier Celis-Gutierrez et al. Cell Reports
- Recruit or Reboot? How Does Anti-PD-1 Therapy Change Tumor-Infiltrating Lymphocytes?
- (2019) Margaret K. Callahan et al. CANCER CELL
- Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
- (2019) Jiajia Zhang et al. CLINICAL CANCER RESEARCH
- TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision
- (2019) Zeyu Chen et al. IMMUNITY
- PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
- (2019) Yunlong Zhao et al. IMMUNITY
- Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
- (2019) William H. Hudson et al. IMMUNITY
- The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals
- (2019) Elliot A. Philips et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
- (2019) Caroline S. Jansen et al. NATURE
- CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities
- (2019) Tomasz Ahrends et al. Nature Communications
- PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+T-Cell–Driven Antitumor Immunity
- (2018) Sarah L. Buchan et al. CLINICAL CANCER RESEARCH
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
- (2018) Xinyi Guo et al. NATURE MEDICINE
- Role of PD-1 during effector CD8 T cell differentiation
- (2018) Eunseon Ahn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- PD-L1 binds to B7-1 only in cis on the same cell surface
- (2018) Apoorvi Chaudhri et al. Cancer Immunology Research
- High-dimensional single cell analysis identifies stem-like cytotoxic CD8+T cells infiltrating human tumors
- (2018) Jolanda Brummelman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma
- (2018) Hanjie Li et al. CELL
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
- (2018) Christopher S. Garris et al. IMMUNITY
- Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
- (2018) Lei Zhang et al. NATURE
- CD8 + T Cells Orchestrate pDC-XCR1 + Dendritic Cell Spatial and Functional Cooperativity to Optimize Priming
- (2017) Anna Brewitz et al. IMMUNITY
- CD4 + T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness
- (2017) Tomasz Ahrends et al. IMMUNITY
- Chromatin states define tumour-specific T cell dysfunction and reprogramming
- (2017) Mary Philip et al. NATURE
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
- (2017) Alice O. Kamphorst et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
- (2017) Janet Lau et al. Nature Communications
- PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
- (2017) Jan Willem Kleinovink et al. OncoImmunology
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
- (2016) T. Ahrends et al. CANCER RESEARCH
- The Basis of Oncoimmunology
- (2016) A. Karolina Palucka et al. CELL
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- T Cell Factor 1-Expressing Memory-like CD8 + T Cells Sustain the Immune Response to Chronic Viral Infections
- (2016) Daniel T. Utzschneider et al. IMMUNITY
- Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
- (2016) Hélène Salmon et al. IMMUNITY
- Immediate Dysfunction of Vaccine-Elicited CD8+T Cells Primed in the Absence of CD4+T Cells
- (2016) Nicholas M. Provine et al. JOURNAL OF IMMUNOLOGY
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Follicular CXCR5-expressing CD8+ T cells curtail chronic viral infection
- (2016) Ran He et al. NATURE
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients
- (2016) Alena Gros et al. NATURE MEDICINE
- Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node
- (2016) Masahiro Kitano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Robust Anti-viral Immunity Requires Multiple Distinct T Cell-Dendritic Cell Interactions
- (2015) Sarah Eickhoff et al. CELL
- Spatiotemporally Distinct Interactions with Dendritic Cell Subsets Facilitates CD4+ and CD8+ T Cell Activation to Localized Viral Infection
- (2015) Jyh Liang Hor et al. IMMUNITY
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Confusing signals: Recent progress in CTLA-4 biology
- (2015) Lucy S.K. Walker et al. TRENDS IN IMMUNOLOGY
- Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
- (2015) A. R. Sanchez-Paulete et al. Cancer Discovery
- Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
- (2014) Christian A. Bauer et al. JOURNAL OF CLINICAL INVESTIGATION
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- High and Interrelated Rates of PD-L1+CD14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer
- (2014) A. M. Heeren et al. Cancer Immunology Research
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
- (2011) Kajsa Wing et al. TRENDS IN IMMUNOLOGY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells
- (2008) L. Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now